PCA
XERS icon

Pallas Capital Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Pallas Capital Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.3K Buy
11,152
+31
+0.3% +$198 ﹤0.01% 958
2026
Q1 		$64.5K Buy
11,121
+118
+1% +$782 ﹤0.01% 818
2025
Q4 		$86.4K Sell
11,003
-24
-0.2% -$189 ﹤0.01% 849
2025
Q3 		$89.8K Buy
11,027
+22
+0.2% +$146 ﹤0.01% 832
2025
Q2 		$51.4K Sell
11,005
-4,338
-28% -$19.9K ﹤0.01% 827
2025
Q1 		$84.2K Buy
+15,343
New +$61.9K ﹤0.01% 712

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Pallas Capital Advisors's XERS Position: Q2 2026 in Review

Pallas Capital Advisors increased its Xeris Biopharma Holdings (XERS) stake by 0.28% in Q2 2026, buying an estimated $198 and bringing the position to 11,152 shares worth $88.3K. The position accounts for ﹤0.01% of the portfolio, ranked #958.

Pallas Capital Advisors first reported a position in XERS in Q1 2025 and has held it in 6 quarters since. The position peaked at $89.8K in Q3 2025. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Pallas Capital Advisors held 11,152 shares of Xeris Biopharma Holdings worth $88.3K as of Q2 2026.
  • Pallas Capital Advisors bought 31 Xeris Biopharma Holdings shares in Q2 2026, an estimated $198.
  • Xeris Biopharma Holdings made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #958 holding.
  • Pallas Capital Advisors first reported a position in Xeris Biopharma Holdings in Q1 2025 and has held it in 6 quarters since.
  • Pallas Capital Advisors's Xeris Biopharma Holdings position peaked at $89.8K in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.